VALBIOTIS Releases Its 2020 Annual Results 2020 highlights and results Global strategic partnership with Nestlé Health Science for the development and marketing of TOTUM-63, a plant-based active substance with clinically proven metabolic health benefits in prediabetic subjects. Launch of REVERSE-IT, a global pivotal Phase II/III clinical trial of TOTUM-63 for reducing Type 2 Diabetes risk factors. New milestones achieved with TOTUM-070, a plant-based active substance for lowering LDL-cholesterol, a risk factor for cardiovascular disease. €14.6m in cash as at December 31, 2020. Post-balance sheet events and outlook Important milestones are expected to be reached in the development of TOTUM-070 (reduction in blood LDL-cholesterol levels).